Last reviewed · How we verify
Plasma Film
At a glance
| Generic name | Plasma Film |
|---|---|
| Sponsor | Vitruvian Medical Devices, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Start Taking Action For TB Diagnosis
- Nicotinamide Levels in Serum, Aqueous Humor, and Tear Film in Glaucoma and Correlations With Mitochondrial Damage-Associated Molecular Patterns (mtDAMPs) and Senescence-Associated Secretory Phenotype (SASP) (NA)
- Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Renal Impairment Compared to Healthy Participants. (PHASE1)
- Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Mild Hepatic Impairment Compared to Participants With Normal Hepatic Function (PHASE1)
- Study to Assess the Safety of DERMASEAL for Diabetic Foot Ulcers (PHASE1)
- Pharmacokinetics of Plasma Doravirine Once Daily Over 72 Hours Following Drug Intake Cessation in Healthy Volunteers (PHASE1)
- Efficacy of the Use of Cellular Matrix/ A-CP-HA Kit (PHASE4)
- Study to Assess the Safety and Efficacy of DERMASEAL for the Treatment of Split-Thickness Skin Graft Donor Site Wounds (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Plasma Film CI brief — competitive landscape report
- Plasma Film updates RSS · CI watch RSS
- Vitruvian Medical Devices, Inc. portfolio CI